首页 产品目录 分子砌块 按官能团 酰胺类 methyl (E)-3-methoxy-2-((3R,6'R,7'S,8a'S)-2-oxo-6'-vinyl-2',3',6',7',8',8a'-hexahydro-5'H-spiro[indoline-3,1'-indolizin]-7'-yl)acrylate

methyl (E)-3-methoxy-2-((3R,6'R,7'S,8a'S)-2-oxo-6'-vinyl-2',3',6',7',8',8a'-hexahydro-5'H-spiro[indoline-3,1'-indolizin]-7'-yl)acrylate

methyl (E)-3-methoxy-2-((3R,6'R,7'S,8a'S)-2-oxo-6'-vinyl-2',3',6',7',8',8a'-hexahydro-5'H-spiro[indoline-3,1'-indolizin]-7'-yl)acrylate

产品编号 :
Cas No. :
包装规格 纯度 目录价 会员专享价 库存 数量

抱歉,暂无牌价信息

晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。

基础信息

CAS No.

630-94-4

英文名称

methyl (E)-3-methoxy-2-((3R,6'R,7'S,8a'S)-2-oxo-6'-vinyl-2',3',6',7',8',8a'-hexahydro-5'H-spiro[indoline-3,1'-indolizin]-7'-yl)acrylate

别名

corynoxeine;(7R,16E,20α)-16,17,18,19-Tetradehydro-17-methoxy-2-oxocorynoxan-16-carboxylic acid methyl ester;(alphaE,1'R,6'R,7'S,8'aS)-6'-Ethenyl-1,2,2',3',6',7',8',8'a-octahydro-alpha-(methoxymethylene)-2-oxospiro[3H-indole-3,1'(5'H)-indolizine]-7'-acetic acid methyl ester;16,17,18,19-Tetradehydro-17-methoxy-2-oxocorynoxan-16-carboxylic acid methyl ester;Spiro[3H-indole-3,1'(5'H)-indolizine]-7'-aceticacid, 6'-ethenyl-1,2,2',3',6',7',8',8'a-octahydro-a-(methoxymethylene)-2-oxo-, methyl ester, (aE,1'R,6'R,7'S,8'aS)-;Corynoxeine, 99.9%;Spiro[3H-indole-3,1'(5'H)-indolizine]-7'-acetic acid, 6'-ethenyl-1,2,2',3',6',7',8',8'a-octahydro-α-(methoxymethylene)-2-oxo-, methyl ester, (αE,1'R,6'R,7'S,8'aS)-;corynoxeine USP/EP/BP

标准英文名

methyl (E)-3-methoxy-2-((3R,6'R,7'S,8a'S)-2-oxo-6'-vinyl-2',3',6',7',8',8a'-hexahydro-5'H-spiro[indoline-3,1'-indolizin]-7'-yl)acrylate

分子式

C22H26N2O4

分子量

382.46

精确分子量

382.19

SMILES

C=C[C@H]1CN2CC[C@]3(C(=O)NC4=CC=CC=C43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC

标准SMILES

CO/C=C(\[C@H]1C[C@@H]2N(C[C@@H]1C=C)CC[C@]12C2=CC=CC=C2NC1=O)/C(=O)OC

用途

Corynoxeine exhibits vasodilatory effects on aortic rings of hypertensive rats, demonstrating peripheral vasodilation, negative inotropic activity, and antihypertensive effects; it can be used in the preparation of vasodilator and antihypertensive drugs. It reduces cardiac afterload and myocardial contractility, thereby decreasing myocardial oxygen consumption, and is applicable in the development of anti-anginal medications, particularly for acute angina treatment. Corynoxeine shows negative inotropic effects and can be used to formulate drugs for ventricular tachycardia. It also elevates the excitation threshold of ventricular myocardium, making it suitable for the preparation of anti-ventricular arrhythmic agents. Additionally, corynoxeine acts as a potent inhibitor of ERK1/ERK2 activation in PDGF-BB-induced vascular smooth muscle cell (VSMC) proliferation, effectively suppressing VSMC proliferation and DNA synthesis without cytotoxicity. It is also used for pharmacological research, content determination, and compound identification. Pharmacologically, it inhibits the respiratory center and isolated intestinal motility, stimulates isolated rat uterine contraction, lowers blood pressure, inhibits platelet aggregation, promotes disaggregation of already aggregated platelets, and improves erythrocyte deformability by protecting against impairing factors. Clinically, it is used in the treatment of hypertension, showing efficacy in stages I and II hypertension.

InChIKey

MUVGVMUWMAGNSY-KAXDATADSA-N

安全信息

SureRoute逆合成路线

1.  630-94-4 逆合成路线 1

—
—
—
—
ACVEFV019
630-94-4
来源: SureRoute

2.  630-94-4 逆合成路线 2

—
—
ACVEFV019
630-94-4
来源: SureRoute

3.  630-94-4 逆合成路线 3

—
—
ACVEFV019
630-94-4
来源: SureRoute
评论 0
我是晶智Agent,
您的化学小助手